{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:32:26Z","timestamp":1793946746163,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.diabres.2026.113272","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:13:11Z","timestamp":1777011191000},"page":"113272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of anagliptin added to metformin and empagliflozin 25\u00a0mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-3068","authenticated-orcid":false,"given":"Jun Sung","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ah","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Chul","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Goo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.diabres.2026.113272_b0005","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4093\/dmj.2025.0978","article-title":"Bridging evidence and practice: a consensus statement from the korean diabetes association on diabetes screening, pharmacological treatment and severe diabetes","volume":"49","author":"Choi","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"4","key":"10.1016\/j.diabres.2026.113272_b0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113272_b0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2026.113272_b0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113272_b0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4093\/dmj.2025.0469","article-title":"Clinical practice guidelines for diabetes management in Korea: recommendation of the Korean diabetes association","volume":"49","author":"Kang","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"3","key":"10.1016\/j.diabres.2026.113272_b0030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4093\/dmj.2025.0220","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application","volume":"49","author":"Bae","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"17","key":"10.1016\/j.diabres.2026.113272_b0035","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.diabres.2026.113272_b0040","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.diabres.2026.113272_b0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113272_b0050","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113272_b0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4093\/dmj.2015.39.5.373","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies","volume":"39","author":"Son","year":"2015","journal-title":"Diabetes Metab J"},{"issue":"5","key":"10.1016\/j.diabres.2026.113272_b0060","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/dom.14959","article-title":"Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: a double-blind, randomized controlled trial","volume":"25","author":"Lee","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"28","key":"10.1016\/j.diabres.2026.113272_b0065","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038870","article-title":"Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: a systematic review and meta-analysis","volume":"103","author":"Kamrul-Hasan","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.diabres.2026.113272_b0070","doi-asserted-by":"crossref","first-page":"44865","DOI":"10.1038\/srep44865","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials","volume":"7","author":"Lyu","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.diabres.2026.113272_b0075","first-page":"320","article-title":"Efficacy and safety of triple therapy with SGLT-2 inhibitor, DPP-4 inhibitor, and metformin in type 2 diabetes: a meta-analysis","volume":"29","author":"Li","year":"2023","journal-title":"Altern Ther Health Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113272_b0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113272_b0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12020-013-0090-0","article-title":"Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients","volume":"46","author":"Esposito","year":"2014","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.diabres.2026.113272_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/ijcp.12761","article-title":"The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial","volume":"70","author":"Zhou","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2026.113272_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/984245","article-title":"Weight considerations in pharmacotherapy for type 2 diabetes","author":"Cheng","year":"2011","journal-title":"J Obes"},{"key":"10.1016\/j.diabres.2026.113272_b0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.diabres.2016.04.055","article-title":"Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality","volume":"117","author":"Eriksson","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.diabres.2026.113272_b0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1463-1326.2011.01473.x","article-title":"Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence","volume":"14","author":"van Genugten","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113272_b0110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113272_b0115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.diabres.2026.113272_b0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00125-016-3899-2","article-title":"Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism","volume":"59","author":"Ahren","year":"2016","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.diabres.2026.113272_b0125","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1111\/dom.16550","article-title":"Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: an updated systematic review and meta-analysis with focus on an Asian subpopulation","volume":"27","author":"Kim","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113272_b0130","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41598-018-22658-2","article-title":"Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis","volume":"8","author":"Min","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.diabres.2026.113272_b0135","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cts.12732","article-title":"Comparison of efficacy of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter 2 inhibitors between Japanese and non-Japanese patients: a meta-analysis","volume":"13","author":"Ito","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.diabres.2026.113272_b0140","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2026.113272_b0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12933-019-0965-3","article-title":"Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial","volume":"18","author":"Chihara","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113272_b0150","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jdi.12860","article-title":"Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport","volume":"9","author":"Goto","year":"2018","journal-title":"J Diabetes Invest"},{"issue":"2","key":"10.1016\/j.diabres.2026.113272_b0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jdi.12593","article-title":"Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice","volume":"8","author":"Yano","year":"2017","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2026.113272_b0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbrc.2022.10.034","article-title":"Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK\/Ta-Ins2(Akita) mice with progressive diabetic kidney disease","volume":"635","author":"Fujita","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.diabres.2026.113272_b0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000391","article-title":"Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner","volume":"5","author":"Kitada","year":"2017","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:59:35Z","timestamp":1793944775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0168822726001919"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113272","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of anagliptin added to metformin and empagliflozin 25\u00a0mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113272"}}